Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $90.00 at Wedbush

Apogee Therapeutics (NASDAQ:APGE) had its target price lifted by Wedbush from $87.00 to $90.00 in a research note issued on Monday, MarketBeat reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 94.55% from the company’s previous close.

APGE has been the subject of a number of other reports. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Guggenheim lifted their price objective on Apogee Therapeutics from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $83.88.

Apogee Therapeutics Trading Up 0.3 %

Shares of APGE stock opened at $46.26 on Monday. The stock has a 50-day moving average price of $53.17 and a 200 day moving average price of $48.33. Apogee Therapeutics has a 12 month low of $18.84 and a 12 month high of $72.29.

Insider Activity

In other news, insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90. Following the sale, the insider now owns 274,128 shares in the company, valued at $15,422,441.28. This represents a 2.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $59.22, for a total value of $888,300.00. Following the sale, the chief executive officer now owns 1,339,487 shares in the company, valued at approximately $79,324,420.14. This represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,330 shares of company stock worth $3,906,508 in the last 90 days. Corporate insiders own 36.10% of the company’s stock.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in shares of Apogee Therapeutics during the 2nd quarter worth approximately $660,000. XTX Topco Ltd acquired a new position in shares of Apogee Therapeutics during the 2nd quarter worth approximately $706,000. Victory Capital Management Inc. increased its holdings in shares of Apogee Therapeutics by 56.8% during the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock worth $6,149,000 after acquiring an additional 56,607 shares during the last quarter. Waypoint Capital Advisors LLC acquired a new position in shares of Apogee Therapeutics during the 3rd quarter worth approximately $36,835,000. Finally, AQR Capital Management LLC acquired a new position in shares of Apogee Therapeutics during the 2nd quarter worth approximately $454,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.